FLT3 INHIBITORS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Santos, A. [1 ]
Pereira, C. [1 ]
Freitas, D. [2 ]
机构：
[1] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
[2] Univ Jose do Rosario Vellano UNIFENAS BH, Belo Horizonte, MG, Brazil
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MT1
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] FLT3 Inhibitors for the Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Systematic Review and Meta-analysis
    André Soares Santos
    Camila Oliveira Pereira
    Daniela Almeida Freitas
    SN Comprehensive Clinical Medicine, 5 (1)
  • [2] A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia
    Mohebbi, Alireza
    Shahriyary, Fahimeh
    Farrokhi, Vida
    Bandar, Bita
    Saki, Najmaldin
    LEUKEMIA RESEARCH, 2024, 141
  • [3] Efficacy Analysis of Different FLT3 Inhibitors in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients - a Systematic Review and Meta-Analysis
    Swaminathan, Mahesh
    MAly, Mai M.
    Akers, Katherine G.
    Kim, Seongho
    Ramos, Harry
    Maciejewski, Jaroslaw P.
    Balasubramanian, Suresh Kumar
    BLOOD, 2021, 138
  • [4] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [5] A Systematic Review and Meta-Analysis Comparing Type I and II FLT3 Inhibitors in Relapsed/ Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Aly, Mai M. M.
    Swaminathan, Mahesh
    Akers, Katherine G.
    Kim, Seongho
    Ramos, Harry
    Maciejewski, Jaroslaw P.
    Balasubramanian, Suresh Kumar
    BLOOD, 2021, 138
  • [6] Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
    Chew, Serena
    Mackey, Melissa C.
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [7] FLT3 inhibitors for relapsed or refractory acute myeloid leukaemia
    Stein, Eytan M.
    LANCET ONCOLOGY, 2018, 19 (07): : 849 - +
  • [8] Difference in FLT3 Mutational Status between Diagnosis and Relapsed/Refractory Acute Myeloid Leukemia: A Meta-Analysis
    Silva, Lais Teixeira
    Campos, Camilla C.
    Salvino, Marco Aurelio
    BLOOD, 2020, 136
  • [9] The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
    Marconi, Giovanni
    Giannini, Maria Benedetta
    Bagnato, Gianmarco
    Simonetti, Giorgia
    Cerchione, Claudio
    Mosquera Orgueira, Adrian
    Musuraca, Gerardo
    Martinelli, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 791 - 799
  • [10] Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis
    Yang, Minglei
    Zhao, Jian
    Liu, Tielong
    Yang, Xinghai
    Wei, Haifeng
    Xu, Wei
    Xiao, Jianru
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 2635 - 2652
12345